CRISPR Therapeutics (CRSP) CFO receives 19,500 RSU equity award

Rhea-AI Filing Summary

Prasad Raju reported acquisition or exercise transactions in this Form 4 filing.

CRISPR Therapeutics AG reported that its Chief Financial Officer, Prasad Raju, received a grant of 19,500 Restricted Stock Units on May 29, 2026. Each RSU represents a contingent right to receive one common share, so this award ties directly to future share ownership.

All 19,500 underlying common shares will vest in a single tranche on November 29, 2028, aligning the CFO’s compensation with the company’s long-term performance. Following this grant, the filing shows 19,500 derivative securities linked to common shares held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Prasad Raju

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	19,500	$0.00	--

Holdings After Transaction: Restricted Stock Units — 19,500 shares (Direct, null)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. This restricted stock unit award was granted on May 29, 2026 with respect to 19,500 Common Shares, with 100% of the shares vesting on November 29, 2028.

Key Figures

RSUs granted: 19,500 units Underlying shares: 19,500 common shares Grant price: $0.00 per unit +2 more

5 metrics

RSUs granted 19,500 units Restricted Stock Units granted to CFO on May 29, 2026

Underlying shares 19,500 common shares Each RSU represents one CRISPR Therapeutics common share

Grant price $0.00 per unit Stated transaction price per Restricted Stock Unit

Vesting date November 29, 2028 100% of 19,500 RSUs vest on this date

Holdings after grant 19,500 derivative securities Total RSUs tied to common shares following the transaction

Key Terms

Restricted Stock Units, grant/award acquisition, vesting

3 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

grant/award acquisition financial

"transaction_action: grant/award acquisition related to 19,500 RSUs"

vesting financial

"100% of the shares vesting on November 29, 2028"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Prasad Raju

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/29/2026		A		19,500		(2)	(2)	Common Shares	19,500	$0	19,500	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

2. This restricted stock unit award was granted on May 29, 2026 with respect to 19,500 Common Shares, with 100% of the shares vesting on November 29, 2028.

	Elizabeth Ryland Waldinger, attorney-in-fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CRISPR Therapeutics (CRSP) report for Prasad Raju?

CRISPR Therapeutics reported a grant of 19,500 Restricted Stock Units to Chief Financial Officer Prasad Raju. The award represents equity-based compensation that links part of the CFO’s pay to the company’s future share performance.

How many CRISPR Therapeutics (CRSP) RSUs were granted in this Form 4?

The filing shows a grant of 19,500 Restricted Stock Units. Each RSU is tied to one common share, giving the CFO a potential future claim on 19,500 CRISPR Therapeutics common shares if vesting conditions are satisfied.

When do the granted CRISPR Therapeutics (CRSP) RSUs vest?

The 19,500 Restricted Stock Units are scheduled to vest 100% on November 29, 2028. This single vesting date encourages longer-term alignment between the CFO’s interests and the company’s multi-year business performance.

Does the CRISPR Therapeutics (CRSP) CFO pay anything for these RSU grants?

No cash purchase is indicated; the RSUs were granted with a stated price of $0.00 per unit. This structure is typical for stock-based compensation awards, which deliver potential future shares if the vesting conditions are met.

What does each CRISPR Therapeutics (CRSP) RSU represent in this filing?

Each Restricted Stock Unit represents a contingent right to receive one CRISPR Therapeutics common share. The filing specifies that all 19,500 RSUs correspond to 19,500 common shares, deliverable upon satisfying the vesting schedule.

Is this CRISPR Therapeutics (CRSP) Form 4 a buy or sell transaction?

The Form 4 reflects an acquisition through a grant or award, not an open-market buy or sell. The CFO received 19,500 RSUs as compensation, with future delivery of shares dependent on vesting.